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ABSTRACT
Objective To evaluate the association of kidney function
with cardiovascular disease and mortality among
apparently healthy women.
Design Prospective cohort study.
Setting Women’s Health Study, United States.
Participants 27939 female health professionals aged
≥45 who were free of cardiovascular disease and other
major disease and who provideda blood sample at study
entry.
Main outcome measures Time to cardiovascular disease
(non-fatal stroke, non-fatal myocardial infarction,
coronary revascularisation procedures, or death from
cardiovascular cause), specific cardiovascular disease
events, and all-cause mortality. End points were
confirmed after review of medical records and death
certificates.
Results Glomerular filtration rate (GFR) was estimated
withtheabbreviatedModificationofDietinRenalDisease
Studyequation.Atbaseline,1315(4.7%)womenhadGFR
<60 ml/min/1.73 m
2. During 12 years of follow-up, 1199
incident cardiovascular disease events and 856 deaths
(179 from cardiovascular disease) occurred. Compared
with women with GFR ≥90 ml/min/1.73 m
2, the
multivariable adjusted hazard ratios for any first
cardiovascular disease were 0.95 (95% CI 0.83 to 1.08),
0.84 (0.70 to 1.00), and 1.00 (0.79 to 1.27) among
women with GFR of 75-89.9, 60-74.9, and <60 ml/min/
1.73 m
2, respectively; the equivalent hazard ratios for all
cause mortality were 0.93 (0.79 to 1.09), 1.03 (0.85 to
1.26), and 1.09 (0.83 to 1.45). Similar null findings were
observed for myocardial infarction, stroke, coronary
revascularisation, and non-cardiovascular death.
However, an increased risk of death from cardiovascular
disease was found among women with GFR <60 ml/min/
1.73 m
2 (hazard ratio 1.68 (1.02 to 2.79)).
Conclusions In this large cohort of women, a glomerular
filtration rate <60 ml/min/1.73 m
2 was associated with
increased risk of cardiovascular disease death but not
other cardiovascular disease events or non-
cardiovascular disease mortality. We observed no
increaseinriskofanyoftheoutcomesamongwomenwith
less severe impairment of kidney function.
Chronickidneydiseaseandcardiovasculardiseaseare
emerging public health problems in the United States
andworldwide,
12andthesetwodiseasesseemtohavea
complex relation.
3-5 For example, the prevalence of
traditional risk factors for cardiovascular disease is
increased in patients with impaired kidney function,
4
andtheseriskfactorspredictthestartofchronickidney
disease.
6-9 Furthermore, several studies suggest an
association between impaired kidney function and
cardiovascular disease as well as mortality from all
causes
10-15 and specifically from cardiovascular
disease.
16 Most studies of the association between kid-
ney function and cardiovascular disease or mortality
havebeenlimitedtoindividualsathighriskforcardio-
vascular disease, with existing cardiovascular disease,
or with severely impaired kidney function.
However, studies of the association between
impaired kidney function and cardiovascular disease
among people not selected on the basis of cardio-
vascular risk or impaired kidney function showed less
consistentresults.
16-19 Wethereforeevaluatedtheasso-
ciation between kidney function and cardiovascular
disease as well as mortality in the prospective
Women’s Health Study among more than 27939
women who were at least 45 years old and did not
have cardiovascular disease or other major disease,
including symptomatic kidney disease, at study entry.
METHODS
Study population
We conducted a prospective cohort study among par-
ticipants in the Women’s Health Study, a completed
randomised placebo controlled trial designed to test
the benefits and risks of low dose aspirin and vitamin
E in the primary prevention of cardiovascular disease
and cancer. The study’s design, methods, and results
have been described in detail previously.
20-22 Briefly, a
total of 39876 US female health professionals aged
≥45 years at study entry (1992-5), who were mostly
white (94%), and without a history of cardiovascular
disease,cancer,orothermajorillnesseswererandomly
assignedto aspirin (100 mgon alternate days),vitamin
E (600 IU on alternate days), both active agents, or
both placebos. All participants provided written
informed consent and the Institutional Review Board
ofBrighamandWomen’sHospital(BostonMA,USA)
approved the study. Baseline information was self
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asked about many cardiovascular risk factors and life-
style variables.
Blood measurements
Bloodsampleswerecollectedfrom28345participants
beforerandomisation.Ofthose,406samplescouldnot
be analysed because of technical limitations, leaving
27939 participants for analysis. All blood samples
were collected in tubes containing EDTA and stored
in vapour phase liquid nitrogen (−170°C). In a core
laboratory certified by the National Heart, Lung, and
Blood Institute-Centers for Disease Control and Pre-
vention Lipid Standardisation Program, samples
were analysed for lipids and a panel of inflammatory
biomarkers. Creatinine was measured by a rate
blanked method that is based on the Jaffé reaction.
Total cholesterol was assayed with reagents from
RocheDiagnostics(Basel,Switzerland)andhighsensi-
tivityCreactiveproteinconcentrationsweremeasured
with immunoturbidimetric assays on a Hitachi 917
analyser (Roche Diagnostics, Indianapolis, USA)
using reagents and calibrators from Denka Seiken
(Tokyo, Japan).
Kidney function
As the primary measure of kidney function, we esti-
mated glomerular filtration rate (GFR) by the abbre-
viated prediction equation developed from the
Modification of Diet in Renal Disease Study,
23 as
recommended by the National Kidney Foundation
24:
Estimated GFR (in ml/min/1.73 m
2) = 186 × [serum
creatinine (in mg/dl)
−1.154 × Age
−0.203 × 0.742 (female)
× 1.210 (if black)]
Wecategorisedparticipantsbasedontheirestimated
GFR as <60, 60-74.9, 75-84.0, and ≥90 ml/min/
1.73m
2,basedontheclassificationoftheNationalKid-
ney Foundation.
24 In sensitivity analyses, we also eval-
uated categories of GFR of <40 ml/min/1.73 m
2 with
risks of cardiovascular disease. We had too few parti-
cipants in lower categories of GFR to perform mean-
ingful analyses.
As a secondary measure for kidney function, we
used plasma creatinine concentration, which we cate-
gorised according to the following centile cut-offs:
<50th (≤0.71 mg/dl, ≤63 μmol/l), 50-74th (0.72-
0.79 mg/dl, 64-70 μmol/l), 75-94th (0.80-1.00 mg/dl,
71-88 μmol/l), and ≥95th (≥1.01 mg/dl, ≥89 μmol/l).
Outcome ascertainment
During follow-up, participants self reported cardio-
vascular eventsand coronaryrevascularisations.Med-
ical records were obtained for all these events and
reviewed by an endpoints committee of physicians.
The occurrence of myocardial infarction was con-
firmed if symptoms met World Health Organization
criteria and if the event was associated with abnormal
levels of cardiac enzymes or diagnostic electrocardio-
grams. Non-fatal stroke was confirmed if the partici-
pant had a new focal-neurological deficit of sudden or
rapid onset that persisted for >24 hours and attributed
to a cerebrovascular event, and was classified into its
major subtypes based on available clinical and diag-
nostic information with excellent interobserver
agreement.
25 Deaths were confirmed by review of
autopsy reports, death certificates, medical records,
or information obtained from next of kin or family
members and classified according to its cause.
The primary outcome was any first cardiovascular
event, a combined end point defined as the first of
any of these events: non-fatal stroke, non-fatal myo-
cardial infarction, coronary revascularisation proce-
dures, or death from cardiovascular disease. We also
evaluated the association between kidney function
with any first individual cardiovascular event, all-
cause mortality, and non-cardiovascular mortality.
Statistical analyses
We compared baseline characteristics of participants
according to GFR categories. To compare mean
response among the categories, we used analyses of
covarianceadjustingforage.Weuseddirectstandardi-
sation to adjust categorical variables and incidence
rates for cardiovascular disease for age in 5-year incre-
ments.
We used Cox proportional hazards models to eval-
uatetheassociationofGFRandplasmacreatininecate-
gories with the various outcomes. We calculated
hazard ratios adjusted for age and for multiple vari-
ables and their 95% confidence intervals. The multi-
variable models controlled for age (continuous),
systolic blood pressure categories (10 mm Hg incre-
ments), antihypertensive treatment (yes, no), smoking
(never, past, current), body mass index (<25, 25-29.9,
≥30 kg/m
2), alcohol consumption (rarely/never, <1
drink/week,1-6drinks/week,≥1drinks/day),exercise
(rarely/never, <1 time/week, 1-3 times/week, ≥4
times/week), total cholesterol concentration (quar-
tiles), C reactive protein concentration (quartiles),
postmenopausal hormone use (never, past, current),
history of diabetes (yes, no), as well as randomised
treatment assignments. We incorporated a missing
valueindicatortothemultivariablemodelsifthenum-
ber of women with missing information on covariates
was >100 or assignedmissinginformation to the refer-
ence or the past user category, if applicable.
Wetestedtheproportionalityassumptionbyinclud-
ing an interaction term for GFR category with person
time in the Cox models and found no statistically sig-
nificant violation.
WeevaluatedwhethertheassociationbetweenGFR
and any cardiovascular disease or all-cause mortality
was modified by age (<55, 55-64, ≥65 years), body
mass index (<25, 25-<30, and ≥30 kg/m
2), history of
hypertension (systolic blood pressure ≥140 mmHg,
diastolic blood pressure ≥90 mm Hg, or use of anti-
hypertensive drugs), smoking status (never, past, cur-
rent), C reactive protein (<10, 10-29, ≥30 mg/l) and
total cholesterol concentration (<5.18, 5.18-6.19,
≥6.22 mmol/l). We checked for significant effect mod-
ification by adding appropriate indicator variables to
RESEARCH
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2
statistics. We calculated P for trend across median
values of the glomerular filtration rate and creatinine
categories. All analyses were performed with SAS
version 9.1 (SAS, Cary, NC); All P values were two
tailed, and a P value <0.05 was considered statistically
significant.
RESULTS
Ofthe27939participatingwomen,14979(53.6%)had
a GFR ≥90 ml/min/1.73 m
2, 8073 (28.9%) had a GFR
of 75-89 ml/min/1.73 m
2, 3572 (12.8%) had a GFR of
60-74 ml/min/1.73 m
2, and 1315 (4.7%) had a GFR
<60 ml/min/1.73 m
2. Table 1 shows the association
between baseline characteristics and GFR categories.
Compared with women with a GFR ≥90 ml/min/
1.73 m
2, women with a rate <60 ml/min/1.73 m
2
were older, had higher totalcholesterol and C reactive
protein values, and were more likely to be
hypertensive and to use antihypertensive drugs, be
past smokers, and be more physically active.
Duringameanof12yearsoffollow-up(339303per-
son years), 1199 participants had at least one incident
cardiovascular event (non-fatal stroke, non-fatal myo-
cardial infarction, coronary revascularisation proce-
dure, or death from a cardiovascular cause) and 856
women died, with 179 of the deaths caused by cardio-
vascular disease. We found no association between
GFR categories and risk of any cardiovascular event
or death from any cause. Compared with women
with GFR ≥90 ml/min/1.73 m
2, the multivariable
adjusted hazard ratios for any first cardiovascular dis-
ease event were 0.95 (95% confidence interval 0.83 to
1.08),0.84(0.70to1.00),and1.00(0.79to1.27)among
women with GFR of 75-89.9, 60-74.9, and <60 ml/
min/1.73 m
2 respectively; and for all-cause mortality
the hazard ratios were 0.93 (0.79 to 1.09), 1.03 (0.85 to
1.26), and 1.09 (0.83 to 1.45) respectively. We further
found no association between GFR and myocardial
infarction, coronary revascularisation procedures,
stroke, or non-cardiovascular death. Comparing
women with a GFR <60 ml/min/1.73 m
2 with
women with a rate of ≥90 ml/min/1.73 m
2, the multi-
variableadjustedhazardratioswere1.03(0.79to1.33)
formyocardialinfarction,0.83(0.59to1.17)forcoron-
aryrevascularisationprocedures,1.03(0.70to1.53)for
stroke, and 0.92 (0.65 to 1.29) for non-cardiovascular
death (table 2). With regard to stroke subtypes, our
data indicated no increased risk for the ischaemic or
haemorrhagic stroke subtype: compared with women
with a GFR ≥90 ml/min/1.73 m
2, women with a rate
<60ml/min/1.73m
2hadadjustedhazardratiosof1.11
(0.73 to 1.69) for ischaemic stroke and 0.66 (0.20 to
2.19) for haemorrhagic stroke.
We found a significantly increased risk of cardio-
vascular death (hazard ratio 1.68 (1.02 to 2.79)) for
women with a GFR <60 ml/min/1.73 m
2 compared
with women with a GFR ≥90 ml/min/1.73 m
2. How-
ever, this increased risk was limited to women in the
low GFR group, and we found no significant linear
trend across GFR categories (table 2).
WhenwefurthersubcategorisedthelowGFRgroup
to <40 ml/min/1.73 m
2, we found increased risk of
death from any cause (hazard ratio 2.26 (1.15 to
4.41)) for the 67 women in that category, which was
driven by increased risk of death from cardiovascular
disease (3.06 (0.94 to 9.94)), when compared with the
high GFR group. In contrast, there was no significant
association with other cardiovascular disease end
points with the highest point estimate for stroke
(hazard ratio 1.31 (0.41 to 4.13)).
Table 3 summarises the association between cate-
gories of creatinine concentration and risk of the var-
ious outcomes. Overall, the pattern of association was
similar to that found with the GFR categories. Com-
pared with women with a creatinine concentration
below the 50th centile, women with concentrations
≥95th centile had multivariable adjusted hazard ratios
of 0.99 (0.78 to 1.26) for any cardiovascular disease,
0.86 (0.51 to 1.43) for myocardial infarction, 0.82
Table 1 |Age adjusted baseline characteristics of 27 939 participants in the Women’sH e a l t h
Study by estimated glomerular filtration rate.* Values are percentages of participants unless
stated otherwise
Characteristics
Glomerular filtration rate (ml/min/1.73 m
2)
<60 (n=1315) 60-74 (n=3572) 75-89 (n=8073) ≥90 (n=14 979)
Mean (SE) age (years) 57.1 (0.22) 56.5 (0.13) 55.2 (0.08) 53.8 (0.05)
Mean (SE) total cholesterol
concentration (mmol/l)
6.59 (0.03) 5.82 (0.02) 5.50 (0.01) 5.29 (0.01)
Mean (SE) C reactive protein
concentration (mg/l)
4.2 (0.16) 3.5 (0.1) 3.4 (0.06) 3.8 (0.05)
Mean (SE) body mass index
(kg/m
2)
26.0 (0.14) 25.9 (0.08) 25.8 (0.06) 26.0 (0.04)
Body mass index ≥30 kg/m
2 18.8 17.1 16.6 18.3
Mean (SE) systolic blood
pressure (mm Hg)
123.9 (0.37) 123.2 (0.22) 123.2 (0.15) 124.1 (0.11)
Hypertension 27.4 25.0 23.7 25.6
Antihypertensive treatment 16.6 14.0 12.4 13.4
Diabetes 2.4 2.1 2.1 2.7
Smoking status:
Never 51.3 51.9 52.8 51.0
Past 37.6 36.7 36.4 36.7
Current 11.1 11.5 10.8 12.3
Alcohol consumption:
Rarely/never 42.7 43.8 42.2 45.3
<1 drink/week 13.1 13.1 13.3 13.4
1-6 drinks/week 34.4 33.2 33.6 31.1
≥1 drinks/day 9.7 9.9 10.9 10.3
Physical activity:
Rarely/never 34.9 36.7 35.4 38.5
<1 time/week 18.5 18.5 19.0 20.1
2-3 times/week 33.1 32.6 33.7 30.7
≥4 times/week 13.6 12.2 12.0 10.7
Postmenopausal hormone
use:
Never 47.6 48.2 49.8 47.9
Past 9.3 9.6 8.9 8.7
Current 43.1 42.2 41.3 43.5
Randomised to aspirin use 49.4 49.8 50.7 49.8
*Estimated with the Modification of Diet in Renal Disease Study equation.
23
Proportions may not add up to 100% because of rounding and missing values.
SE = standard error.
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 3 of 7(0.58to1.16)forcoronaryrevascularisation,0.99(0.66
to1.47)forstroke,1.10(0.83to1.46)forall-causemor-
tality, 1.74 (1.05 to 2.89) for cardiovascular mortality,
and 0.92 (0.65 to 1.29) for non-cardiovascular mortal-
ity.
Lastly,wedidnotfindevidencethatthelackofasso-
ciation between GFR and overall cardiovascular dis-
ease was modified by age (P interaction=0.19), body
mass index (P interaction=0.49), history of hyperten-
sion (P interaction=0.14), smoking status (P inter-
action=0.92), and total cholesterol concentration (P
interaction=0.65). With regard to all-cause mortality,
we found significant effect modification by history of
hypertension (P interaction=0.02) suggesting
increased risk of death from any cause for women
with a history of hypertension (hazard ratio 1.31 (0.92
to 1.86)). The association between GFR and all-cause
mortality was not modified by age, body mass index,
smoking status, or total cholesterol (all P interaction
≥0.1).
DISCUSSION
Inthislargeprospectivecohortofmostlywhitewomen
who were aged ≥45 and free of cardiovascular disease
andothermajordiseaseincludingsymptomatickidney
diseaseatstudyentry,we didnotobserveanincreased
risk of any cardiovascular disease event or mortality
for the more than 11000 women with GFR between
60 and 89 ml/min/1.73 m
2, data we believe both
important and reassuring given recent suggestions of
a link between renal impairment and incident cardio-
vascular disease. Our results further indicate that a
GFR <60 ml/min/1.73 m
2 seemed to be associated
with increased risk of cardiovascular death but not
withanyotherfirstcardiovasculareventornon-cardio-
vascularmortalitywhencomparedwithwomenwitha
GFR ≥90 ml/min/1.73 m
2. When we evaluated creati-
nine concentration rather than estimated GFR, the
associations with cardiovascular disease and mortality
were similar.
Comparison with other studies
Several studies have found increased risk of cardio-
vascular disease for individuals with impaired kidney
function.
10131426-28 However, most of these studies
were of patients with existing cardiovascular disease
or who were at high risk for cardiovascular disease or
werelimitedtoindividualsaged65andabove.
26-28Two
Table 2 |Hazard ratios (95% confidence intervals) for cardiovascular events and mortality among 27 939 participants in the
Women’s Health Study by estimated glomerular filtration rate.* Hazard ratios are adjusted for age and for multiple
variables†
Event
Glomerular filtration rate (ml/min/1.73 m
2)
P value for trend‡ <60 (n=1315) 60-74 (n=3572) 75-89 (n=8073) ≥90 (n=14 979)
Any cardiovascular event
(n=1199)§:
(n=84) (n=165) (n=347) (n=603)
Age adjusted 1.13 (0.90 to 1.42) 0.86 (0.73 to 1.03) 0.93 (0.81 to 1.06) 1.00 0.53
Multiple adjusted 1.00 (0.79 to 1.27) 0.84 (0.70 to 1.00) 0.95 (0.83 to 1.08) 1.00 0.22
Myocardial infarction (n=313): (n=17) (n=50) (n=94) (n=152)
Age adjusted 0.91 (0.55 to 1.50) 1.04 (0.75 to 1.43) 1.00 (0.77 to 1.29) 1.00 0.91
Multiple adjusted 1.03 (0.79 to 1.33) 0.99 (0.71 to 1.37) 0.80 (0.48 to 1.34) 1.00 0.63
Coronary revascularisation
(n=675)¶:
(n=39) (n=90) (n=197) (n=349)
Age adjusted 0.96 (0.69 to 1.33) 0.86 (0.68 to 1.08) 0.93 (0.78 to 1.11) 1.00 0.27
Multiple adjusted 0.83 (0.59 to 1.17) 0.81 (0.64 to 1.02) 0.95 (0.80 to 1.14) 1.00 0.08
Stroke (n=389): (n=31) (n=50) (n=111) (n=197)
Age adjusted 1.20 (0.82 to 1.77) 0.76 (0.55 to 1.04) 0.88 (0.70 to 1.12) 1.00 0.52
Multiple adjusted 1.03 (0.70 to 1.53) 0.74 (0.54 to 1.02) 0.90 (0.71 to 1.14) 1.00 0.29
All-cause mortality (n=856): (n=60) (n=139) (n=236) (n=421)
Age adjusted 1.10 (0.84 to 1.45) 1.00 (0.82 to 1.21) 0.88 (0.75 to 1.04) 1.00 0.99
Multiple adjusted 1.09 (0.83 to 1.45) 1.03 (0.85 to 1.26) 0.93 (0.79 to 1.09) 1.00 0.77
Cardiovascular disease death
(n=179):
(n=21) (n=32) (n=43) (n=83)
Age adjusted 1.77 (1.09 to 2.88) 1.07 (0.71 to 1.62) 0.78 (0.54 to 1.13) 1.00 0.18
Multiple adjusted 1.68 (1.02 to 2.79) 1.18 (0.77 to 1.79) 0.87 (0.60 to 1.27) 1.00 0.13
Non-cardiovascular disease
death (n=677):
(n=39) (n=107) (n=193) (n=338)
Age adjusted 0.92 (0.66 to 1.28) 0.98 (0.78 to 1.22) 0.91 (0.76 to 1.09) 1.00 0.48
Multiple adjusted 0.92 (0.65 to 1.29) 1.00 (0.65 to 1.25) 0.94 (0.79 to 1.13) 1.00 0.62
*Estimated with the Modification of Diet in Renal Disease Study equation.
23
†Adjusted for age, systolic blood pressure, antihypertensive treatment, smoking, body mass index, alcohol consumption, exercise, total cholesterol, C
reactive protein, use of hormone replacement therapy, diabetes, and assigned treatments.
‡P for trend across median values of the GFR categories.
§Defined as the first of any of non-fatal stroke, non-fatal myocardial infarction, coronary revascularisation procedure, or death from cardiovascular
cause.
¶Includes reports of bypass surgery or percutaneous coronary angioplasty.
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spectiveCardiovascularHealthStudy,whichincluded
individuals aged 65 and above. The first evaluated the
association between creatinine concentration and
cardiovascular outcomes.
27 Results indicated steadily
increasing risk of all-cause mortality, cardiovascular
mortality, non-cardiovascular mortality, overall
cardiovascular disease, and congestive heart failure
with increasing levels of creatinine. The second study
assessed several measures of kidney function—includ-
ing creatinine levels, estimated GFR, and cystatin C
concentration—all of which were associated with
increased risk of all-cause mortality, cardiovascular
mortality, myocardial infarction, and stroke.
26 How-
ever, participants in the Cardiovascular Health Study
were older and were considerably sicker than partici-
pants in the Women’s Health Study and included
patients with existing cardiovascular disease, conges-
tive heart failure, and cancer, which may explain the
differentfindingscomparedwithourstudywithregard
to non-fatal cardiovascular disease.
Inalarge,communitybasedstudyusingadministra-
tive data, impaired GFR was strongly associated with
all-cause mortality, cardiovascular events, and rates of
hospitalisation.
13 However, the evaluated GFR ranges
were much lower than in our study, and individuals
with prior stroke, transient ischaemic attacks, periph-
eral artery disease, and chronic heart failure were
included. Compared with participants with a GFR
≥60 ml/min/1.73 m
2, participants with a GFR
<15 ml/min/1.73 m
2 had adjusted hazard ratios ran-
ging from 3.1 (95% confidence interval 3.0 to 3.3) for
anyhospitalisationto5.9(5.4to6.5)fordeathfromany
cause.Anotherstudyshowedsimilarresultsindicating
that patients with prior myocardial infarction and
severe renal dysfunction (GFR <45 ml/min/1.73 m
2)
had increased risk for recurrent coronary events.
29
However, even in this high risk population, risks
were not increasedamongthose withlessseverelevels
of kidney impairment (GFR 60-74 ml/min/1.73 m
2).
When we further subdivided our low GRF group to
values of <40 ml/min/1.73 m
2, we observed increased
riskofall-causemortality,whichwasdrivenbycardio-
vascular mortality. However, we only had 67 women
in this category, which limits any interpretation of
these findings.
Further, in a cohort of 37153 individuals who were
screenedin the National Kidney Foundation’s Kidney
EarlyEvaluationProgramandwhowerefollowedfora
median of 16 months, three measures of chronic
Table 3 |Hazard ratios (95% confidence intervals) for cardiovascular events and mortality among 27 939 participants in the
Women’s Health Study by blood creatinine concentration. Hazard ratios are adjusted for age and for multiple variables*
Event
Creatinine concentration (centiles)†
P value for trend‡ <50th (n=14 043) 50-74th (n=6900) 75-94th (n=5598) ≥95th (n=1398)
Any cardiovascular event
(n=1199)§:
N=604 N=275 N=239 N=81
Age adjusted 1.00 0.90 (0.78 to 1.04) 0.91 (0.78 to 1.05) 1.14 (0.90 to 1.44) 0.95
Multiple adjusted 1.00 0.92 (0.80 to 1.06) 0.89 (0.77 to 1.04) 0.99 (0.78 to 1.26) 0.41
Myocardial infarction (n=313): N=146 N=81 N=69 N=17
Age adjusted 1.00 1.10 (0.84 to 1.45) 1.08 (0.81 to 1.44) 0.99 (0.60 to 1.64) 0.76
Multiple adjusted 1.00 1.13 (0.86 to 1.49) 1.06 (0.79 to 1.42) 0.86 (0.51 to 1.43) 0.83
Coronary revascularisation
(n=675)¶:
N=342 N=161 N=134 N=38
Age adjusted 1.00 0.94 (0.78 to 1.13) 0.91 (0.75 to 1.12) 0.97 (0.69 to 1.35) 0.51
Multiple adjusted 1.00 0.95 (0.79 to 1.15) 0.87 (0.71 to 1.07) 0.82 (0.58 to 1.16) 0.13
Stroke (n=389): N=206 N=80 N=74 N=29
Age adjusted 1.00 0.77 (0.59 to 0.99) 0.81 (0.62 to 1.05) 1.17 (0.79 to 1.72) 0.73
Multiple adjusted 1.00 0.78 (0.60 to 1.01) 0.80 (0.61 to 1.04) 0.99 (0.66 to 1.47) 0.34
All-cause mortality (n=856): N=433 N=179 N=186 N=58
Age adjusted 1.00 0.82 (0.69 to 0.97) 0.97 (0.82 to 1.15) 1.13 (0.86 to 1.49) 0.74
Multiple adjusted 1.00 0.85 (0.71 to 1.01) 1.01 (0.85 to 1.20) 1.10 (0.83 to 1.46) 0.67
Cardiovascular disease death
(n=179):
N=84 N=34 N=41 N=20
Age adjusted 1.00 0.80 (0.54 to 1.19) 1.07 (0.74 to 1.56) 1.91 (1.17 to 3.12) 0.03
Multiple adjusted 1.00 0.87 (0.58 to 1.30) 1.18 (0.80 to 1.72) 1.74 (1.05 to 2.89) 0.04
Non-cardiovascular disease
death (n=677):
N=349 N=145 N=145 N=38
Age adjusted 1.00 0.82 (0.68 to 1.00) 0.95 (0.78 to 1.15) 0.93 (0.66 to 1.30) 0.45
Multiple adjusted 1.00 0.84 (0.69 to 1.03) 0.97 (0.80 to 1.18) 0.92 (0.65 to 1.29) 0.51
*Adjusted for age, systolic blood pressure, antihypertensive treatment, smoking, body mass index, alcohol consumption, exercise, total cholesterol, C
reactive protein, use of hormone replacement therapy, diabetes, and assigned treatments.
†Equivalent to ≤63 μmol/l, 64-70 μmol/l, 71-88 μmol/l, ≥89 μmol/l.
‡P for trend across median values of the creatinine categories.
§Defined as the first of any of non-fatal stroke, non-fatal myocardial infarction, coronary revascularisation procedure, or death from cardiovascular
cause.
¶Includes reports of bypass surgery or percutaneous coronary angioplasty.
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2,microalbu-
minuria >30 mg/l, and anaemia) were associated with
increased risk of death. Further, participants who had
allthreefactorspresenthadthelowestsurvival.
30Inthe
Women’s Health Study no information on microalbu-
minuria or anaemia was available.
With regard to stroke subtypes, findings from the
Rotterdam Study indicated increased risk of haemor-
rhagic stroke for individuals with decreased kidney
function.
31 Compared with participants with the high-
est quarter of GFR values, those with the lowest values
had a hazard ratio (adjusted for age and sex) of 4.10
(1.25to13.42).Ourdatadonotindicateanassociation
betweenkidneyfunctionandhaemorrhagicstroke,but
the low numberof such events in our study(n=73)and
in the Rotterdam Study (n=44) means the results
should be interpreted cautiously. Similar to our data,
there was no association with ischaemic stroke in the
data from the Netherlands.
The overall epidemiological evidence associating
impaired kidney function with risk of cardiovascular
disease and mortality suggests that individuals with a
GFR <60 ml/min/1.73 m
2 are at increased risk of
cardiovascular death, and the risk steadily increases
with decreasing GFR values below 60. The increased
risk ofmyocardial infarctionand stroke aswell asnon-
cardiovascularmortality may be limited to individuals
with existingcardiovascular disease or whoare at high
risk for cardiovascular disease events. In addition,
patients with GFR <30 ml/min/1.73 m
2 may be at
increased risk for all cardiovascular disease events
and all-cause mortality.
The association between kidney function and
cardiovascular disease is complex. It has been shown
that risk factors for cardiovascular disease also predict
impaired kidney function. For example, in the Fra-
mingham Heart Study, body mass index, smoking,
and diabetes are predictors of impaired kidney
function.
7 Furthermore, data from the Physicians’
Health Study indicated that higher cholesterol levels,
6
high body mass index,
9 and abstaining from drinking
alcohol
8 were risk factors for chronic kidney disease.
Thus, impaired kidney function may be a marker for
individuals with a more unfavourable cardiovascular
disease risk profile and not a biological risk factor per
se for subsequent cardiovascular disease.
Strengths and limitations of study
Our study has several strengths, including the large
number of participants and outcome events, high par-
ticipation rate and long follow-up, confirmed cardio-
vascular disease events after medical record review,
the homogeneity of the study (which may reduce
bias), and available information on a large number of
potential confounding factors.
Severallimitationsshouldbeconsideredwheninter-
preting our results. First, creatinine concentration was
measured only once, and thus change of creatinine
over time could not be evaluated.
Second, we used the Modification of Diet in Renal
Disease Study equation to estimate GFR, which may
resultinmisclassificationofkidneyfunction.However,
the equation predicts GFR well, and its use is recom-
mend by the National Kidney Foundation.
24 In addi-
tion, when we used creatinine categories or the
Cockcroft-Gault equation
32 (data not shown) to esti-
mate kidney function, we found a similar pattern of
association between impaired kidney function and
cardiovascular disease events. We had no other mea-
sures of impaired kidney function available, such as
microalbuminuria or cystatin C. Cystatin C may be a
bettermarkerofchronickidneydiseasethancreatinine
and may be a better predictor for cardiovascular
disease.
28
Third, despite adjustment for a large number of
potential confounders, residual and unmeasurable
confounding may be present since our data are obser-
vational.
Fourth, although the overall number of outcome
eventswaslarge,wehadlimitednumbersofindividual
events in each of the GFR subgroups, so our findings
should be interpreted cautiously.
Lastly, all participants were female health profes-
sionals and most of them white, which may limit gen-
eralisability to other populations. Indeed, data suggest
that the association between impaired kidney function
and cardiovascular disease or mortality is more appar-
ent in black people
14 and men.
18
Conclusions
Data from this large prospective cohort of women
without prior cardiovascular disease or other major
disease at study entry do not indicate an association
between mild to moderate kidney impairment and
increased risk of cardiovascular disease or mortality.
Impaired kidney function (GFR <60 ml/min/
1.73 m
2) seemed to be associated with an increased
risk of cardiovascular disease death but not other
cardiovascular or mortality outcomes, a finding that
deserves further investigations.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Impaired kidney function has been associated with increased risk of cardiovascular disease
and mortality amongpatientswithexistingkidneydisease orexistingcardiovasculardisease
WHAT THIS STUDY ADDS
This large prospective study of women free of vascular disease or symptomatic kidney
disease at baseline indicates no association between kidney function and major
cardiovascular disease or all-cause mortality
Impaired kidney function (glomerular filtration rate <60 ml/min/1.73 m
2) seemed to be
associated with an increased risk of cardiovascular disease death but was not associated
with any other cardiovascular or mortality outcome
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